The antibody MEM-G/2 recognizes an extracellular epitope on free heavy chain of all the HLA-G isoforms. HLA-G belongs to the MHC Class I molecules (MHC Class Ib, nonclassical) and it is expressed on the surface of trophoblast cells.
Réactivité croisée (Details)
Human
Purification
Purified by protein-A affinity chromatography.
Pureté
> 95 % (by SDS-PAGE)
Immunogène
Bacterially expressed recombinant HLA-G heavy chain (denatured).
Phosphate buffered saline (PBS), pH 7.4, 15 mM sodium azide
Agent conservateur
Sodium azide
Précaution d'utilisation
This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
Conseil sur la manipulation
Do not freeze.
Stock
4 °C
Stockage commentaire
Store at 2-8°C. Do not freeze.
Kren, Slaby, Muckova, Lzicarova, Sova, Vybihal, Svoboda, Fadrus, Lakomy, Vanhara, Krenova, Sterba, Smrcka, Michalek: "Expression of immune-modulatory molecules HLA-G and HLA-E by tumor cells in glioblastomas: An unexpected prognostic significance?" dans: Neuropathology : official journal of the Japanese Society of Neuropathology, (2010) (PubMed).
Le Discorde, Moreau, Sabatier, Legeais, Carosella: "Expression of HLA-G in human cornea, an immune-privileged tissue." dans: Human immunology, Vol. 64, Issue 11, pp. 1039-44, (2003) (PubMed).
Poláková, Bandzuchová, Hofmeister, Weiss, Hutter, Russ: "Binding analysis of HLA-G specific antibodies to hematopoietic cells isolated from leukemia patients." dans: Neoplasma, Vol. 50, Issue 5, pp. 331-8, (2003) (PubMed).
Boyson, Erskine, Whitman, Chiu, Lau, Koopman, Valter, Angelisova, Horejsi, Strominger: "Disulfide bond-mediated dimerization of HLA-G on the cell surface." dans: Proceedings of the National Academy of Sciences of the United States of America, Vol. 99, Issue 25, pp. 16180-5, (2002) (PubMed).
Antigène
HLAG
(HLA Class I Histocompatibility Antigen, alpha Chain G (HLAG))
anticorps MHC-G, anticorps B-F, anticorps B-F-S04, anticorps B-F-S05, anticorps B-F-S06, anticorps B-F-S07, anticorps B-FI, anticorps B-FIV, anticorps BF2, anticorps BFa2, anticorps BFw-03, anticorps BFw-05, anticorps BFz-01, anticorps major histocompatibility complex, class I, G, anticorps MHC BF1 class I, anticorps HLA-G, anticorps BF1
Sujet
Major histocompatibility complex, class I, G,Human leukocyte antigen G (HLA-G), belonging to MHC class I glycoproteins, plays important roles in both physiological and pathological immunotolerance. It gives an inhibitory signal to cytotoxic T cells, NK cells, monocytes, and some other immune cells. It also induces regulatory T cells and anti-inflammatory macrophages. HLA-G is important e.g. for maternal tolerance to the fetus, and for immunomodulation in particular adult tissues, such as in cornea, pancreatic islets, thymus and other. On the other hand, it is expressed in many solid and hematologic malignancies, where it contributes to evasion of the immune surveillance. HLA-G expression pattern in cancer is an important prognostic factor regarding a poor clinical outcome. Unlike most other MHC glycoproteins, HLA-G acts as an immune checkpoint molecule rather than as an antigen presenting molecule. It concerns both transmembrane and soluble HLA-G isoforms. Among other, HLA-G can promote Th2 immunological response and downregulate Th1 immunological response. For its benefits regarding allograft tolerance, including embryo implantation, soluble HLA-G (sHLA-G) can be used as a marker of developmental potential of embryos during the process of in vitro fertilization. Similarly, sHLA-G concentrations in maternal serum are decreased in preeclampsia. Transplanted patients with increased sHLA-G serum levels have improved allograft acceptance. On the other hand, increased sHLA-G can also indicate presence of malignant (sometimes also of benign) tumor cells. Another important topic is induction of HLA-G expression (sometimes associated with shedding of HLA-G from the cell surface) by some anti-cancer or anti-viral therapies, which can weaken the therapy effect. Monitoring of HLA-G in patients thus has a wide usage.